On the public citation graph

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

https://doi.org/10.1056/nejmoa1814468
0 signed · 873 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archinte.164.15.1653openalex-snapshot
Outcomes and Cost of Deep Venous Thrombosis Among Patients With Cancer
inferredcites →https://doi.org/10.1001/archinte.164.2.190openalex-snapshot
Symptomatic Venous Thromboembolism in Cancer Patients Treated With Chemotherapy
inferredcites →https://doi.org/10.1002/14651858.cd008500.pub2openalex-snapshot
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
inferredcites →https://doi.org/10.1016/j.thromres.2015.08.002openalex-snapshot
Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis
inferredcites →https://doi.org/10.1016/j.thromres.2017.01.009openalex-snapshot
Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial
inferredcites →https://doi.org/10.1016/j.thromres.2018.01.018openalex-snapshot
Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial
inferredcites →https://doi.org/10.1016/j.thromres.2018.01.028openalex-snapshot
Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer
inferredcites →https://doi.org/10.1016/s1470-2045(09)70232-3openalex-snapshot
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
inferredcites →https://doi.org/10.1056/nejm200012213432504openalex-snapshot
Prognosis of Cancers Associated with Venous Thromboembolism
inferredcites →https://doi.org/10.1056/nejmoa1108898openalex-snapshot
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
inferredcites →https://doi.org/10.1056/nejmoa1711948openalex-snapshot
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
inferredcites →https://doi.org/10.1111/j.1538-7836.2005.01204.xopenalex-snapshot
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
inferredcites →https://doi.org/10.1111/j.1538-7836.2006.01804.xopenalex-snapshot
Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study
inferredcites →https://doi.org/10.1111/j.1538-7836.2009.03678.xopenalex-snapshot
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
inferredcites →https://doi.org/10.1111/j.1538-7836.2012.04693.xopenalex-snapshot
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-06-1210openalex-snapshot
Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis
inferredcites →https://doi.org/10.1160/th16-12-0946openalex-snapshot
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists
inferredcites →https://doi.org/10.1182/blood-2002-01-0108openalex-snapshot
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
inferredcites →https://doi.org/10.1182/blood-2007-10-116327openalex-snapshot
Development and validation of a predictive model for chemotherapy-associated thrombosis
inferredcites →https://doi.org/10.1182/blood-2010-02-270116openalex-snapshot
Prediction of venous thromboembolism in cancer patients
inferredcites →https://doi.org/10.1200/jco.2014.59.7351openalex-snapshot
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
inferredcites →https://doi.org/10.1200/jco.2018.78.8034openalex-snapshot
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
inferredcites →https://doi.org/10.1214/aos/1176350951openalex-snapshot
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
inferredcites →https://doi.org/10.3324/haematol.2017.169060openalex-snapshot
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4054506openalex-extracted
Low-Dose DOACs in Very High-Risk MPNs: Less Bleeding But More Arterial Thrombotic Events
inferred← citeshttps://doi.org/10.1001/jamacardio.2022.1292openalex-snapshot
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.0010openalex-snapshot
Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.2338openalex-snapshot
Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.44428openalex-snapshot
Validation of a Risk Score for Cancer-Associated Thrombosis Using Nationwide EHR Data
inferred← citeshttps://doi.org/10.1001/jamaneurol.2024.2404openalex-snapshot
Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke
inferred← citeshttps://doi.org/10.1001/jamaoncol.2023.2934openalex-snapshot
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
inferred← citeshttps://doi.org/10.1001/jamaoncol.2023.3634openalex-snapshot
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers
inferred← citeshttps://doi.org/10.1002/14651858.cd006466.pub7openalex-snapshot
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation
inferred← citeshttps://doi.org/10.1002/14651858.cd006652.pub3openalex-snapshot
Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
inferred← citeshttps://doi.org/10.1002/14651858.cd008500.pub5openalex-snapshot
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
inferred← citeshttps://doi.org/10.1002/14651858.cd013399openalex-snapshot
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
inferred← citeshttps://doi.org/10.1002/14651858.cd013399.pub2openalex-snapshot
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm131.pub2openalex-snapshot
Coagulation Complications of Cancer Patients
inferred← citeshttps://doi.org/10.1002/9781119823766.ch49openalex-snapshot
Anticoagulation in Cancer
inferred← citeshttps://doi.org/10.1002/acg2.73openalex-snapshot
Cancer‐associated thrombosis: Where do we stand?
inferred← citeshttps://doi.org/10.1002/ajh.25459openalex-snapshot
Apixaban for the prevention of thromboembolism in immunomodulatory‐treated myeloma patients: Myelaxat, a phase 2 pilot study
inferred← citeshttps://doi.org/10.1002/ajh.25603openalex-snapshot
Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score
inferred← citeshttps://doi.org/10.1002/ajh.25604openalex-snapshot
Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer‐associated venous thromboembolism
inferred← citeshttps://doi.org/10.1002/ajh.25837openalex-snapshot
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma ‐ specific venous thrombosis prediction models
inferred← citeshttps://doi.org/10.1002/ajh.26623openalex-snapshot
Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations
inferred← citeshttps://doi.org/10.1002/ajh.26806openalex-snapshot
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival
inferred← citeshttps://doi.org/10.1002/ajh.26928openalex-snapshot
External validation of a novel electronic risk score for cancer‐associated thrombosis in a comprehensive cancer center
inferred← citeshttps://doi.org/10.1002/ajh.26945openalex-snapshot
Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial
inferred← citeshttps://doi.org/10.1002/ajh.27273openalex-snapshot
Assessing hypercoagulability and VTE risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy
inferred← citeshttps://doi.org/10.1002/ajh.27335openalex-snapshot
Thrombosis risk prediction in lymphoma patients: A m ulti‐institutional , retrospective model development and validation study
inferred← citeshttps://doi.org/10.1002/ajh.70271openalex-snapshot
Epidemiology of Cancer‐Associated Venous Thromboembolism Across the United States
inferred← citeshttps://doi.org/10.1002/ajh.70394openalex-snapshot
Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study
inferred← citeshttps://doi.org/10.1002/bcp.70300openalex-snapshot
Neck‐vein thrombosis during spaceflight
inferred← citeshttps://doi.org/10.1002/bjs.11209openalex-snapshot
Scientific Surgery May 2019 BJS
inferred← citeshttps://doi.org/10.1002/bjs.11665openalex-snapshot
Thromboembolic and bleeding complications in patients with oesophageal cancer
inferred← citeshttps://doi.org/10.1002/brb3.2738openalex-snapshot
Cancer‐related stroke: Exploring personalized therapy strategies
inferred← citeshttps://doi.org/10.1002/cam4.3437openalex-snapshot
Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels
inferred← citeshttps://doi.org/10.1002/cam4.3670openalex-snapshot
Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study
inferred← citeshttps://doi.org/10.1002/cam4.4241openalex-snapshot
Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban
inferred← citeshttps://doi.org/10.1002/cam4.4280openalex-snapshot
Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma
inferred← citeshttps://doi.org/10.1002/cam4.70510openalex-snapshot
Incidence, Risk Factors, and Modified Risk Assessment Model of Venous Thromboembolism in Non‐Hodgkin Lymphoma Patients
inferred← citeshttps://doi.org/10.1002/cncr.32423openalex-snapshot
Pancreatic cancer—A disease in need: Optimizing and integrating supportive care
inferred← citeshttps://doi.org/10.1002/cncr.32724openalex-snapshot
Cost‐effectiveness analysis of low‐dose direct oral anticoagulant (DOAC) for the prevention of cancer‐associated thrombosis in the United States
inferred← citeshttps://doi.org/10.1002/cncr.34937openalex-snapshot
Cancer‐associated thrombosis and drug–drug interactions of antithrombotic and antineoplastic agents
inferred← citeshttps://doi.org/10.1002/cncr.70266openalex-snapshot
Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents
inferred← citeshttps://doi.org/10.1002/cpdd.1446openalex-snapshot
Clinical Implications of Co‐administering Apixaban with Key Interacting Medications
inferred← citeshttps://doi.org/10.1002/hem3.70177openalex-snapshot
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network
inferred← citeshttps://doi.org/10.1002/jca.70072openalex-snapshot
Challenges in Trials in Sickle Cell Disease: Thromboprophylaxis in Sickle Cell Disease With Central Venous Catheters ( THIS ) Pilot Study
inferred← citeshttps://doi.org/10.1002/jum.15701openalex-snapshot
Vascular Imaging in the Asymptomatic High‐risk Cancer Population
inferred← citeshttps://doi.org/10.1002/med.21992openalex-snapshot
The new direction of drug development: Degradation of undruggable targets through targeting chimera technology
inferred← citeshttps://doi.org/10.1002/onco.13540openalex-snapshot
D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer
inferred← citeshttps://doi.org/10.1002/onco.13569openalex-snapshot
Prediction and Prevention of Cancer-Associated Thromboembolism
inferred← citeshttps://doi.org/10.1002/onco.13596openalex-snapshot
Update on Guidelines for the Management of Cancer-Associated Thrombosis
inferred← citeshttps://doi.org/10.1002/onco.13698openalex-snapshot
Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies
inferred← citeshttps://doi.org/10.1002/phar.70149openalex-snapshot
Thrombosis Across Female‐Specific Malignancies: From Chemotherapy‐Driven Risk to Prophylaxis and Drug Interactions
inferred← citeshttps://doi.org/10.1002/rcr2.831openalex-snapshot
Multiple cerebral infarctions in ROS1 ‐rearranged lung adenocarcinoma
inferred← citeshttps://doi.org/10.1002/rth2.12210openalex-snapshot
Studies in upper extremity deep vein thrombosis: Addressing the knowledge gaps
inferred← citeshttps://doi.org/10.1002/rth2.12327openalex-snapshot
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
inferred← citeshttps://doi.org/10.1002/rth2.12342openalex-snapshot
A risk score for prediction of venous thromboembolism in gynecologic cancer: The Thrombogyn score
inferred← citeshttps://doi.org/10.1002/rth2.12411openalex-snapshot
Venous thromboembolism in multiple myeloma is associated with increased mortality
inferred← citeshttps://doi.org/10.1002/rth2.12414openalex-snapshot
Anticoagulation practice patterns in COVID‐19: A global survey
inferred← citeshttps://doi.org/10.1002/rth2.12415openalex-snapshot
Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy
inferred← citeshttps://doi.org/10.1002/rth2.12431openalex-snapshot
Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis
inferred← citeshttps://doi.org/10.1002/rth2.12517openalex-snapshot
Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM‐Line): A two‐center open‐label pilot randomized controlled trial
inferred← citeshttps://doi.org/10.1002/rth2.12549openalex-snapshot
Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial
inferred← citeshttps://doi.org/10.1002/rth2.12634openalex-snapshot
Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma
inferred← citeshttps://doi.org/10.1002/rth2.12653openalex-snapshot
Cancer‐associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study
inferred← citeshttps://doi.org/10.1002/rth2.12744openalex-snapshot
Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment—A report from ICTHIC 2021
inferred← citeshttps://doi.org/10.1002/rth2.12749openalex-snapshot
Tumor‐expressed microRNAs associated with venous thromboembolism in colorectal cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-20315-3_1openalex-snapshot
Thrombosis and Hemostasis in Cancer. Scope of the Problem and Overview
inferred← citeshttps://doi.org/10.1007/978-3-030-20315-3_4openalex-snapshot
Risk of Thrombosis in Cancer: Clinical Factors and Role of Primary Prophylaxis
inferred← citeshttps://doi.org/10.1007/978-3-030-25782-8_5openalex-snapshot
Cancer-Associated Thrombosis (CAT)
inferred← citeshttps://doi.org/10.1007/978-3-030-67123-5_24openalex-snapshot
Venous Thromboembolism
inferred← citeshttps://doi.org/10.1007/978-3-030-67123-5_37openalex-snapshot
Bleeding and Thrombosis
inferred← citeshttps://doi.org/10.1007/978-3-030-70904-4_29-1openalex-snapshot
Pulmonary Embolism in Patients with Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-71155-9_20openalex-snapshot
Venous Thromboembolism in Cancer Patients
inferred← citeshttps://doi.org/10.1007/978-3-030-74462-5_10openalex-snapshot
Direct Oral Anticoagulation in Cancer Patients
inferred← citeshttps://doi.org/10.1007/978-3-030-74462-5_2openalex-snapshot
Clinical Indications for Direct Acting Oral Anticoagulants
inferred← citeshttps://doi.org/10.1007/978-3-030-87090-4_16openalex-snapshot
Pulmonary Embolism in Cancer Patients
inferred← citeshttps://doi.org/10.1007/978-3-030-97687-3_14openalex-snapshot
Venous thromboembolism and Cancer
inferred← citeshttps://doi.org/10.1007/978-3-031-41413-8_11openalex-snapshot
Treatment and Prevention of Venous Thromboembolism
inferred← citeshttps://doi.org/10.1007/978-3-032-13858-3_42openalex-snapshot
Bleeding and Thrombosis in a Cancer Patient
inferred← citeshttps://doi.org/10.1007/978-3-662-46764-0_313-1openalex-snapshot
Gerinnungsstörungen bei Tumorpatienten
inferred← citeshttps://doi.org/10.1007/978-3-662-60880-7_138openalex-snapshot
Malignomassoziierte venöse Thromboembolie
inferred← citeshttps://doi.org/10.1007/978-3-662-61379-5_138-1openalex-snapshot
Malignomassoziierte venöse Thromboembolie
inferred← citeshttps://doi.org/10.1007/978-981-16-6494-6_6openalex-snapshot
Haematological Prehabilitation
inferred← citeshttps://doi.org/10.1007/978-981-96-1285-7_6openalex-snapshot
Management of Cancer‑Associated Thrombosis and Related Complications
inferred← citeshttps://doi.org/10.1007/s00059-020-04961-9openalex-snapshot
Prevention and treatment of venous thromboembolism in cancer patients
inferred← citeshttps://doi.org/10.1007/s00105-022-05056-8openalex-snapshot
Gerinnungsstörungen bei Tumorerkrankungen
inferred← citeshttps://doi.org/10.1007/s00108-025-01967-5openalex-snapshot
Verlängerte Rezidivprophylaxe bei krebsassoziierter venöser Thromboembolie – API-CAT schafft Klarheit
inferred← citeshttps://doi.org/10.1007/s00120-024-02273-yopenalex-snapshot
Primäre Thromboseprophylaxe zur Vermeidung von venösen Thromboembolien bei ambulanten Tumorpatienten unter Chemotherapie
inferred← citeshttps://doi.org/10.1007/s00210-021-02190-3openalex-snapshot
Coagulation markers in patients with venous thromboembolism treated with 10 mg apixaban twice daily
inferred← citeshttps://doi.org/10.1007/s00277-024-05733-9openalex-snapshot
Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines
inferred← citeshttps://doi.org/10.1007/s00280-025-04826-0openalex-snapshot
Thrombosis and cancer what do the recommandations say
inferred← citeshttps://doi.org/10.1007/s00392-026-02872-zopenalex-snapshot
Antithrombotic therapy for cancer-associated venous thromboembolism
inferred← citeshttps://doi.org/10.1007/s00415-020-09775-7openalex-snapshot
A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place
inferred← citeshttps://doi.org/10.1007/s00432-021-03794-1openalex-snapshot
Predictors for thromboembolism in patients with cholangiocarcinoma
inferred← citeshttps://doi.org/10.1007/s00520-022-07138-8openalex-snapshot
Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?
inferred← citeshttps://doi.org/10.1007/s00520-022-07297-8openalex-snapshot
Catheter-related thrombosis (CRT) in patients with solid tumors: a narrative review and clinical guidance for daily care
inferred← citeshttps://doi.org/10.1007/s00520-022-07433-4openalex-snapshot
Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1007/s00761-019-0618-xopenalex-snapshot
Kardiovaskuläre Nebenwirkungen moderner Tumortherapien – die richtige Balance
inferred← citeshttps://doi.org/10.1007/s00761-020-00879-3openalex-snapshot
Thromboembolische Komplikationen und Thromboseprophylaxe bei fortgeschrittenen testikulären Keimzelltumoren
inferred← citeshttps://doi.org/10.1007/s00761-022-01132-9openalex-snapshot
Gerinnungsstörungen bei Tumorerkrankungen
inferred← citeshttps://doi.org/10.1007/s00772-020-00630-7openalex-snapshot
9. Jahrestagung der Vereinigung der interdisziplinären Gefäßmediziner Süddeutschlands (VIGS)
inferred← citeshttps://doi.org/10.1007/s10120-023-01415-zopenalex-snapshot
Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study
inferred← citeshttps://doi.org/10.1007/s10147-022-02257-yopenalex-snapshot
Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data
inferred← citeshttps://doi.org/10.1007/s10741-020-09994-0openalex-snapshot
Direct oral anticoagulants across the heart failure spectrum: the precision medicine era
inferred← citeshttps://doi.org/10.1007/s11239-019-01845-6openalex-snapshot
Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients
inferred← citeshttps://doi.org/10.1007/s11239-019-01891-0openalex-snapshot
What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial
inferred← citeshttps://doi.org/10.1007/s11239-020-02317-yopenalex-snapshot
Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial
inferred← citeshttps://doi.org/10.1007/s11239-021-02537-wopenalex-snapshot
Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma
inferred← citeshttps://doi.org/10.1007/s11239-023-02856-0openalex-snapshot
A nomogram for predicting the risk of venous thromboembolism in patients with solid cancers
inferred← citeshttps://doi.org/10.1007/s11239-023-02908-5openalex-snapshot
Incidence of venous thromboembolism and predictive ability of age-adjusted international prognostic index for prediction of venous thromboembolism in Asian patients with diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1007/s11239-024-02984-1openalex-snapshot
Primary thromboprophylaxis in cancer outpatients – real-world evidence
inferred← citeshttps://doi.org/10.1007/s11239-024-03043-5openalex-snapshot
Real-world data on direct oral anticoagulants in BCR::ABL1-negative myeloproliferative neoplasms (MPNs): a multicenter retrospective study on behalf of scientific subcommittee on MPNs for Turkish society of hematology
inferred← citeshttps://doi.org/10.1007/s11239-025-03122-1openalex-snapshot
Practical considerations about management of pulmonary embolism in patients with cancer
inferred← citeshttps://doi.org/10.1007/s11239-025-03151-wopenalex-snapshot
Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding
inferred← citeshttps://doi.org/10.1007/s11239-025-03156-5openalex-snapshot
Intravenous thrombolysis in the context of stroke and cancer
inferred← citeshttps://doi.org/10.1007/s11239-026-03253-zopenalex-snapshot
Coagulation disorders and thromboprophylaxis in pancreatic cancer: a review of current evidence and clinical challenges
inferred← citeshttps://doi.org/10.1007/s11654-019-00169-4openalex-snapshot
Kardiovaskuläre Nebenwirkungen moderner Tumortherapien – die richtige Balance
inferred← citeshttps://doi.org/10.1007/s11654-020-00249-wopenalex-snapshot
Tumorassoziierte venöse Thromboembolie – Pathogenese, Diagnose, Prävention und Therapie
inferred← citeshttps://doi.org/10.1007/s11739-023-03306-8openalex-snapshot
Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive
inferred← citeshttps://doi.org/10.1007/s11864-020-00744-wopenalex-snapshot
Venous Thromboembolism Treatment and Prevention in Cancer Patients: Can We Use Pills Yet?
inferred← citeshttps://doi.org/10.1007/s11864-023-01089-wopenalex-snapshot
Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges
inferred← citeshttps://doi.org/10.1007/s11912-023-01358-9openalex-snapshot
Prophylactic Anticoagulation in Patients with Cancer: When and How?
inferred← citeshttps://doi.org/10.1007/s11912-023-01428-yopenalex-snapshot
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
inferred← citeshttps://doi.org/10.1007/s11936-019-0764-xopenalex-snapshot
Prevention and Treatment of Cancer-Associated Venous Thromboembolism: a Review
inferred← citeshttps://doi.org/10.1007/s11936-023-00998-1openalex-snapshot
Current Management of Cancer-Associated Thromboembolism in the Prophylactic and Acute Setting
inferred← citeshttps://doi.org/10.1007/s11940-020-00624-6openalex-snapshot
Advancements in the Treatment of Cerebrovascular Complications of Cancer
inferred← citeshttps://doi.org/10.1007/s12029-021-00718-7openalex-snapshot
Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies
inferred← citeshttps://doi.org/10.1007/s12094-019-02263-zopenalex-snapshot
SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)
inferred← citeshttps://doi.org/10.1007/s12094-020-02336-4openalex-snapshot
The effectiveness and safety of thromboprophylaxis in cancer patients based on Khorana score: a meta-analysis and systematic review of randomized controlled trials
inferred← citeshttps://doi.org/10.1007/s12094-020-02506-4openalex-snapshot
Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
inferred← citeshttps://doi.org/10.1007/s12094-021-02735-1openalex-snapshot
Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH
inferred← citeshttps://doi.org/10.1007/s12094-024-03605-2openalex-snapshot
SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023)
inferred← citeshttps://doi.org/10.1007/s12181-019-00362-3openalex-snapshot
Kardiovaskuläre Nebenwirkungen moderner Tumortherapien – die richtige Balance
inferred← citeshttps://doi.org/10.1007/s12185-020-02928-4openalex-snapshot
New insights on patient-related risk factors for venous thromboembolism in patients with solid organ cancers
inferred← citeshttps://doi.org/10.1007/s12185-023-03690-zopenalex-snapshot
Cancer-associated thrombosis in hematologic malignancies
inferred← citeshttps://doi.org/10.1007/s12254-019-0491-8openalex-snapshot
Update in thrombosis and hemostasis: ASH meeting 2018
inferred← citeshttps://doi.org/10.1007/s15004-019-6566-1openalex-snapshot
DOAK auch für Krebspatienten geeignet?
inferred← citeshttps://doi.org/10.1007/s15004-020-8136-yopenalex-snapshot
Therapie und Prophylaxe der tumor-assoziierten venösen Thromboembolie
inferred← citeshttps://doi.org/10.1007/s15006-019-0269-2openalex-snapshot
Thromboseprophylaxe bei Chemotherapie?
inferred← citeshttps://doi.org/10.1007/s15015-019-0161-zopenalex-snapshot
Apixaban zur Thromboseprophylaxe bei Tumorpatienten
inferred← citeshttps://doi.org/10.1007/s15027-019-1518-0openalex-snapshot
NOAK auch zur Primärprophylaxe venöser Thromboembolien bei Krebspatienten geeignet?
inferred← citeshttps://doi.org/10.1007/s40137-021-00293-7openalex-snapshot
Current Management of Acute Pulmonary Embolism
inferred← citeshttps://doi.org/10.1007/s40256-022-00524-xopenalex-snapshot
Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data
inferred← citeshttps://doi.org/10.1007/s40256-024-00638-4openalex-snapshot
Trends in Oral Anticoagulant Use and Individual Expenditures Across the United States from 2014 to 2020
inferred← citeshttps://doi.org/10.1007/s40256-024-00664-2openalex-snapshot
Apixaban Use in Patients with Kidney Impairment: A Review of Pharmacokinetic, Interventional, and Observational Study Data
inferred← citeshttps://doi.org/10.1007/s40261-020-00926-2openalex-snapshot
New Oral Anticoagulants for Thromboprophylaxis in Patients with Cancer Receiving Chemotherapy: An Economic Evaluation in a Chinese Setting
inferred← citeshttps://doi.org/10.1007/s40265-019-01084-2openalex-snapshot
Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1016/b978-0-12-818781-4.00003-0openalex-snapshot
Prevention of thrombosis
inferred← citeshttps://doi.org/10.1016/b978-0-323-68135-3.00018-0openalex-snapshot
Thromboembolic disease prevention before cancer therapy
inferred← citeshttps://doi.org/10.1016/b978-0-323-91208-2.00003-2openalex-snapshot
Venous thromboembolic prophylaxis
inferred← citeshttps://doi.org/10.1016/b978-2-294-76375-5.00034-8openalex-snapshot
Cancer et thrombose
inferred← citeshttps://doi.org/10.1016/b978-3-437-21011-2.00011-9openalex-snapshot
Gerinnung
inferred← citeshttps://doi.org/10.1016/b978-3-437-23824-6.00011-0openalex-snapshot
Gerinnung
inferred← citeshttps://doi.org/10.1016/bs.acc.2023.02.006openalex-snapshot
D-dimer testing: A narrative review
inferred← citeshttps://doi.org/10.1016/j.acvd.2023.11.010openalex-snapshot
Anticoagulant treatment of cancer-associated thromboembolism
inferred← citeshttps://doi.org/10.1016/j.ahjo.2022.100143openalex-snapshot
Vascular disease in cancer: Current and emerging concepts
inferred← citeshttps://doi.org/10.1016/j.ajhg.2022.04.001openalex-snapshot
Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches
inferred← citeshttps://doi.org/10.1016/j.amcp.2020.03.001openalex-snapshot
Anticoagulants oraux directs dans la maladie thromboembolique veineuse associée aux cancers
inferred← citeshttps://doi.org/10.1016/j.amjmed.2019.12.001openalex-snapshot
Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative
inferred← citeshttps://doi.org/10.1016/j.annemergmed.2019.11.010openalex-snapshot
Should Cancer Patients Receive Apixaban to Prevent Venous Thromboembolism? An Analysis of the AVERT Trial
inferred← citeshttps://doi.org/10.1016/j.annonc.2020.11.003openalex-snapshot
Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up
inferred← citeshttps://doi.org/10.1016/j.annonc.2022.12.014openalex-snapshot
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
inferred← citeshttps://doi.org/10.1016/j.avsg.2020.11.007openalex-snapshot
Risk and Management of Venous Thromboembolism in Patients with COVID-19
inferred← citeshttps://doi.org/10.1016/j.bbcan.2023.189053openalex-snapshot
Cancer-associated thrombosis: What about microRNAs targeting the tissue factor coagulation pathway?
inferred← citeshttps://doi.org/10.1016/j.bbcan.2025.189457openalex-snapshot
Cancer-associated thrombosis in cholangiocarcinoma: Exploring a phenotype of tumor aggressiveness
inferred← citeshttps://doi.org/10.1016/j.beha.2022.101347openalex-snapshot
Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps
inferred← citeshttps://doi.org/10.1016/j.beha.2022.101348openalex-snapshot
A review of latest clinical practice guidelines for the management of cancer-associated thrombosis
inferred← citeshttps://doi.org/10.1016/j.beha.2022.101351openalex-snapshot
Thromboprophylaxis of cancer patients undergoing systemic therapy in the ambulatory setting
inferred← citeshttps://doi.org/10.1016/j.beha.2022.101353openalex-snapshot
Thrombosis and bleeding in hematological malignancy
inferred← citeshttps://doi.org/10.1016/j.bulcan.2019.11.007openalex-snapshot
Héparines de bas poids moléculaires dans la maladie thromboembolique veineuse liée au cancer : quelle place en 2019 ?
inferred← citeshttps://doi.org/10.1016/j.bulcan.2020.02.010openalex-snapshot
Place des anticoagulants oraux directs dans la prise en charge de la maladie thromboembolique veineuse associée au cancer en 2020
inferred← citeshttps://doi.org/10.1016/j.bulcan.2020.06.001openalex-snapshot
Une avancée majeure pour le traitement de la maladie thromboembolique veineuse en contexte néoplasique
inferred← citeshttps://doi.org/10.1016/j.bulcan.2022.10.008openalex-snapshot
Prévention et prise en charge des thromboses associées au cancer: questions pratiques à propos de l’anticoagulation
inferred← citeshttps://doi.org/10.1016/j.bulcan.2023.06.001openalex-snapshot
Maladie thromboembolique veineuse et cancer du sein
inferred← citeshttps://doi.org/10.1016/j.bvth.2025.100054openalex-snapshot
Hematologists’ comfort and experiences with providing care to transgender youth
inferred← citeshttps://doi.org/10.1016/j.bvth.2025.100074openalex-snapshot
Association of risk factors for venous thromboembolism and overall survival in lung cancer
inferred← citeshttps://doi.org/10.1016/j.clgc.2019.12.021openalex-snapshot
Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy
inferred← citeshttps://doi.org/10.1016/j.clgc.2022.10.005openalex-snapshot
Primary Thromboprophylaxis and the Risk of Venous Thromboembolic Events in Patients With Testicular Germ Cell Tumors Treated With Cisplatinum-Based Chemotherapy
inferred← citeshttps://doi.org/10.1016/j.clgc.2023.09.005openalex-snapshot
Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1016/j.clgc.2026.102563openalex-snapshot
International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
inferred← citeshttps://doi.org/10.1016/j.clml.2020.11.015openalex-snapshot
Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug–Based Regimens
inferred← citeshttps://doi.org/10.1016/j.clml.2021.07.028openalex-snapshot
Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium
inferred← citeshttps://doi.org/10.1016/j.clml.2023.02.004openalex-snapshot
Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review
inferred← citeshttps://doi.org/10.1016/j.clon.2020.03.013openalex-snapshot
Venous Thromboembolism During Chemotherapy for Testicular Cancer: A Population-Based Study
inferred← citeshttps://doi.org/10.1016/j.cpccr.2024.100348openalex-snapshot
Early onset venous and arterial thrombosis when combining Osimertinib and Amivantamab in NSCLC: Instructive cases and literature review
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2020.103125openalex-snapshot
Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management
inferred← citeshttps://doi.org/10.1016/j.ctarc.2022.100547openalex-snapshot
Profile of metastatic lung cancer patients susceptible to development of thromboembolism during immunotherapy
inferred← citeshttps://doi.org/10.1016/j.ctrv.2026.103180openalex-snapshot
Management of cancer-associated thrombosis in patients with gastrointestinal cancers: lights and shadows
inferred← citeshttps://doi.org/10.1016/j.currproblcancer.2021.100832openalex-snapshot
Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors
inferred← citeshttps://doi.org/10.1016/j.ejim.2019.10.033openalex-snapshot
Management of venous thromboembolism in cancer patients: Considerations about the clinical practice guideline update of the American society of clinical oncology
inferred← citeshttps://doi.org/10.1016/j.ejim.2020.02.024openalex-snapshot
The guidelines they are a changin’
inferred← citeshttps://doi.org/10.1016/j.ejim.2020.03.005openalex-snapshot
Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment
inferred← citeshttps://doi.org/10.1016/j.ejim.2022.02.020openalex-snapshot
Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence
inferred← citeshttps://doi.org/10.1016/j.ejim.2022.07.020openalex-snapshot
Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis
inferred← citeshttps://doi.org/10.1016/j.ejogrb.2024.12.027openalex-snapshot
Risk factors for venous thromboembolism in patients undergoing neoadjuvant chemotherapy as treatment for ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.esmoop.2024.103631openalex-snapshot
Vascular fingerprint tool to identify patients with testicular cancer treated with cisplatin-based chemotherapy at high risk of early cardiovascular events
inferred← citeshttps://doi.org/10.1016/j.esmoop.2024.104130openalex-snapshot
The Vienna CATScore for predicting cancer-associated venous thromboembolism: an external validation across multiple time points
inferred← citeshttps://doi.org/10.1016/j.euf.2020.09.017openalex-snapshot
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy
inferred← citeshttps://doi.org/10.1016/j.euros.2021.07.007openalex-snapshot
Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000–2014: A Population-based Cohort Study
inferred← citeshttps://doi.org/10.1016/j.eururo.2019.10.019openalex-snapshot
Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer
inferred← citeshttps://doi.org/10.1016/j.eururo.2021.02.032openalex-snapshot
Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
showing the first 200 of 849 · page through all 849
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.